Eilber F R, Mirra J J, Grant T T, Weisenburger T, Morton D L
Ann Surg. 1980;192(4):431-8. doi: 10.1097/00000658-198010000-00001.
The rationale for amputation for local tumor control of skeletal and soft tissue sarcomas was based on results obtained from surgical therapy alone. However, our previous results from a pilot trial of multimodality therapy of preoperative chemotherapy and radiation therapy followed by surgical resection indicated that limb salvage (without amputation) could be accomplished in most patients with little morbidity and low recurrence rate. This report summarizes our experience in a prospective trial from January 1972 to December 1979. A total of 105 consecutive patients with soft tissue sarcomas (65 patients) or bone sarcomas (40 patients) were treated with preoperative intraarterial adriamycin, 3500 rads of rapid-fraction radiation and radical en bloc resection of primary tumor. Diseased bones were replaced with cadaver allografts (22 patients), metallic endoprostheses (10 patients) autologous bone (2 patients), or no replacement (ilium or fibula-4 patients). Salvage of a viable, neurologically intact, functional extremity was achieved in 98/105 patients (98%); 97% of limb salvage patients were free of local recurrence after a median follow-up period of 28 months. Major complication rate that required amputation was 3/105 patients (2%). Postoperative adjuvant chemotherapy with cyclical adriamycin and high-dose methotrexate was employed for all patients with osteosarcoma and 35 patients with grade III soft tissue sarcomas. The overall disease-free rate is 50% (18/35) for osteosarcomas and 65% (42/65) for soft tissue sarcomas. These results indicate that local tumor control can be achieved in 91% of patients without amputation. Their functional capabilities are excellent with a low complication rate. Since the advent of adriamycin and methotrexate has significantly improved the overall survival for patients with skeletal and soft tissue sarcomas, the quality of this survival has become even more important. Preoperative multimodality therapy is a major advance in this direction and since results of limb salvage procedures appear to be equal or superior to those achieved by amputation we believe these alternatives should be offered to all patients.
对骨骼和软组织肉瘤进行截肢以实现局部肿瘤控制的理论依据是基于单纯手术治疗所取得的结果。然而,我们之前一项术前化疗和放疗后行手术切除的多模式治疗试点试验的结果表明,大多数患者可以实现保肢(不截肢),且并发症发生率低、复发率也低。本报告总结了我们在1972年1月至1979年12月一项前瞻性试验中的经验。共有105例连续的软组织肉瘤患者(65例)或骨肉瘤患者(40例)接受了术前动脉内阿霉素治疗、3500拉德的快速分割放疗以及原发肿瘤的根治性整块切除。病变骨骼用尸体同种异体骨(22例)、金属假体(10例)、自体骨(2例)进行置换,或不进行置换(髂骨或腓骨 - 4例)。105例患者中有98例(98%)成功保留下了有活力、神经功能完整且功能正常的肢体;保肢患者在中位随访期28个月后,97%无局部复发。需要截肢的主要并发症发生率为105例患者中的3例(2%)。所有骨肉瘤患者以及35例III级软组织肉瘤患者术后均采用了阿霉素和高剂量甲氨蝶呤的辅助化疗。骨肉瘤的总体无病生存率为50%(18/35),软组织肉瘤为65%(42/65)。这些结果表明,91%的患者无需截肢即可实现局部肿瘤控制。他们的功能状态良好,并发症发生率低。自从阿霉素和甲氨蝶呤问世以来,显著提高了骨骼和软组织肉瘤患者的总体生存率,这种生存质量变得更加重要。术前多模式治疗是朝着这个方向迈出的重要一步,而且由于保肢手术的结果似乎等同于或优于截肢手术,我们认为应该为所有患者提供这些替代方案。